Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered NY-ESO-1-Specific (c259) T Cells, Alone or in Combination With Other Agents, in HLA-A2+ Participants With NY-ESO-1 and/or LAGE-1a Positive Solid Tumors (IGNYTE-ESO)

Next Previous
Trial Profile

Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered NY-ESO-1-Specific (c259) T Cells, Alone or in Combination With Other Agents, in HLA-A2+ Participants With NY-ESO-1 and/or LAGE-1a Positive Solid Tumors (IGNYTE-ESO)

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Nov 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Letetresgene autoleucel (Primary) ; Cyclophosphamide; Fludarabine
  • Indications Myxoid liposarcoma; Synovial sarcoma
  • Focus Registrational; Therapeutic Use
  • Acronyms IGNYTE-ESO
  • Sponsors Adaptimmune; GlaxoSmithKline; GlaxoSmithKline Research & Development; GSK

Most Recent Events

  • 13 Nov 2024 According to an Adaptimmune media release, Adaptimmune will host a virtual event to review the IGNYTE-ESO dataset and the impact of engineered cells on the treatment of sarcoma. The event will feature Dr. Sandra D'Angelo, sarcoma medical oncologist of Memorial Sloan Kettering Cancer Center, an investigating clinician in both the SPEARHEAD and IGNYTE-ESO clinical trials, lead author and presenter of the IGNYTE-ESO data update at CTOS.
  • 13 Nov 2024 According to an Adaptimmune media release, full primary analysis on 64 patients with long term follow up from pivotal IGNYTE-ESO trial has been completed and will be presented on 16 Nov 2024, 10:30 AM - 12:00 PM PST, at the Connective Tissue Oncology Society (CTOS) annual meeting, being held in San Diego, CA from November 13 to 16, 2024.
  • 12 Aug 2024 According to an Adaptimmune media release, the company is planning to commence our rolling BLA submission for lete-cel in 2025 and commercial launch in 2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top